Why the study?
Does trimetazidine improve echocardiographic and exercise parameters in patients with cardiomyopathy?
Population
898 patients with cardiomyopathy
Comparison
Trimetazidine (TMZ) vs Control group
Design
Meta-analysis
Key result
Trimetazidine treatment significantly increased left ventricular ejection fraction in patients with cardiomyopathy (95% CI 5.46-7.84; P<0.001).
Authors
Loading...
Supports adjunctive trimetazidine in cardiomyopathy; confirms LVEF benefits across pooled trials.
Meta-Analysis (n=898)
Does trimetazidine improve echocardiographic and exercise parameters in patients with cardiomyopathy?
Trimetazidine treatment significantly improves left ventricular ejection fraction and reduces left ventricular volumes and dimensions in patients with cardiomyopathy.
p-value: p=<0.001
Fan et al. (2018) conducted a meta-analysis in cardiomyopathy (n=898). Trimetazidine vs. Control was evaluated on Left ventricular ejection fraction (LVEF) (95% CI 5.46-7.84, p=<0.001). Trimetazidine treatment significantly increased left ventricular ejection fraction in patients with cardiomyopathy (95% CI 5.46-7.84; P<0.001).